Can testosterone therapy affect lipoprotein(a) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testosterone Therapy and Lipoprotein(a) Levels

Testosterone therapy can reduce lipoprotein(a) [Lp(a)] levels by approximately 20-60% in men with elevated baseline Lp(a) (>25 nmol/L or >30 mg/dL), while having minimal to no effect in those with low baseline levels.

Effect Based on Baseline Lp(a) Levels

The impact of testosterone on Lp(a) is highly dependent on pre-treatment concentrations:

  • Men with elevated Lp(a) (>25 nmol/L or >30 mg/dL): Testosterone therapy produces a significant and consistent reduction in Lp(a) ranging from 25-59%, with the effect being proportional to baseline levels 1, 2.

  • Men with low Lp(a) (<25 nmol/L): No significant decrease in Lp(a) is observed with testosterone treatment 1.

  • Dose-dependent effects: Physiologic replacement doses of testosterone (200-250 mg weekly intramuscularly) lower Lp(a) by approximately 20% 3, 2, while the effect is more pronounced in those with higher baseline values 1.

Mechanism and Reversibility

The Lp(a)-lowering effect of testosterone appears to be:

  • Reversible: Lp(a) levels return to baseline following cessation of testosterone administration 1.

  • Independent of apo(a) size polymorphism: The response to testosterone does not appear related to apolipoprotein(a) isoform size 1.

  • Hepatically mediated: The effect likely depends on testosterone's capability to influence hepatic metabolic pathways of Lp(a) 3.

Route of Administration Matters

The mode of testosterone delivery influences the Lp(a) response:

  • Parenteral (intramuscular) testosterone: Consistently lowers Lp(a) by 20% in men with elevated baseline levels 3, 2.

  • Transdermal testosterone: The New England Journal of Medicine guidelines note that transdermal administration appears to have minimal effects on lipid profiles overall 4, though specific Lp(a) data for transdermal routes is limited in the provided evidence.

Clinical Context: Overall Lipid Effects

While testosterone reduces Lp(a) in appropriate patients, the overall lipid profile effects are complex 4:

  • HDL cholesterol: May decrease minimally with physiologic doses, particularly with supraphysiologic doses (>600 mg weekly) 4.

  • LDL cholesterol and total cholesterol: Generally unchanged or reduced with physiologic replacement doses 4.

  • Net cardiovascular effect: The New England Journal of Medicine guidelines suggest a neutral effect of testosterone-replacement therapy on lipid profiles when used within the physiologic range 4.

Important Caveats

Testosterone suppression (hypogonadism) increases Lp(a): Conversely, suppression of endogenous testosterone significantly increases median Lp(a) levels by 40-60% in individuals with baseline Lp(a) >3 mg/dL 5. This underscores the regulatory role of testosterone on Lp(a) metabolism.

Clinical significance of Lp(a) reduction: While testosterone can lower Lp(a) in men with elevated levels, Lp(a) >30-50 mg/dL or >75-125 nmol/L is associated with increased cardiovascular risk 4. The cardiovascular benefit of testosterone-induced Lp(a) reduction has not been definitively established in outcome trials 4.

Monitoring considerations: Given that elevated Lp(a) affects 20-30% of the global population and is a causal risk factor for cardiovascular disease 4, measuring baseline Lp(a) before initiating testosterone therapy may help identify patients who could derive additional cardiovascular benefit from the Lp(a)-lowering effect.

References

4
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What are the graded cardiovascular risks associated with elevated lipoprotein(a) concentrations?
What is the recommended primary‑prevention treatment strategy according to Canadian guidelines for a 40‑year‑old male with total cholesterol 5.8 mmol/L, LDL 4.24 mmol/L, HDL 0.91 mmol/L, lipoprotein(a) 224 mg/dL, a strong family history of premature coronary artery disease (father with MI in his 50s and triple bypass in his 70s), who is not diabetic, not on any medication, does not smoke tobacco but uses one cannabis joint daily?
Should sertraline (Zoloft) 50 mg be changed in a 35‑year‑old woman who has been stable on it for a year but reports somnolence, has vitamin D deficiency, low folate, normal liver enzymes, and borderline high LDL and total cholesterol?
What is a normal fasting LDL‑cholesterol level for adults?
What are the current guidelines for initiating lipid‑lowering medication based on LDL‑cholesterol levels and cardiovascular risk?
In a 78‑year‑old woman on chronic prednisone who has elevated ristocetin‑induced platelet agglutination, increased von Willebrand factor antigen with normal multimers, normal prothrombin time and activated partial thromboplastin time, normal factor VIII activity, fibrinogen 415 mg/dL, and presents with epistaxis, easy bruising, and idiopathic peripheral edema with normal BNP, creatinine, and liver function tests, is the prednisone the cause of the edema and the mild bruising/epistaxis?
How should I manage a patient with a heterogeneous thyroid on ultrasound and a normal thyroid‑stimulating hormone (TSH) level?
When should colonoscopy screening begin for average‑risk adults and for high‑risk individuals such as those with a first‑degree relative with colorectal cancer or inflammatory bowel disease?
A patient on valproic acid 500 mg twice daily, quetiapine 400 mg at bedtime, and haloperidol 5 mg at bedtime (reduced from 10 mg due to akathisia) still has insomnia; what additional sleep‑promoting medication can be given?
What are the subtypes of prolymphocytic leukaemia in the latest International Consensus Classification?
When is it appropriate to add medical-grade honey to a pressure injury?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question